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To determine the receptor binding properties of various H9 influenza virus escape mutants in the presence and absence of antibody,
sialyloligosaccharides conjugated with biotinylated polyacrylamide were used. A mutant virus with a L226Q substitution showed an
increased affinity for the Neu5Aca2-3Galh1-4Glc. Several escape mutants viruses carrying the mutation N193D bound to Neu5Aca2-
6Galh1-4GlcNAc considerably stronger than to Neu5Aca2-6Galh1-4Glc. Several monoclonal antibodies unable to neutralize the escape
mutants preserved the ability to bind to the hemagglutinin as revealed by enzyme-linked immunosorbent assay. In each case, the bound
monoclonal antibodies did not prevent the binding of the mutant HA to high affinity substrates and did not displace them from the virus
binding sites. Together, these data suggest that amino acid changes selected by antibody pressure may be involved in the specificity of host-
cell recognition by H9 hemagglutinin and in the ability of viruses with these mutations to escape the neutralizing effect of antibodies in a
differential way, depending on the specificity of the host cell receptor. It may be important in the natural evolution of the H9 subtype, a
plausible candidate for the agent likely to cause a future pandemic.
D 2004 Elsevier Inc. All rights reserved.
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The hemagglutinin (HA) and neuraminidase (NA) of
influenza viruses circulating in humans accumulate amino
acid changes that can confer resistance to the neutralizing
effect of antibodies. This process, called antigenic drift, has
been extensively studied, especially in influenza viruses of
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Abbreviations: Neu5Ac, N-acetylneuraminic acid; 3VSL, Neu5Aca2-3-
Galh1-4Glc-, 3V-sialyllactose; 6VSL, Neu5Aca2-6-Galh1-4Glc, 6V-sialyllactose;
6VSLN, Neu5Aca2-6-Galh1-4GlcNAc, 6V-sialyl-(N-acetyllactosamine); PAA,
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substitutions that confer resistance to antibodies can be
artificially selected by treatment with monoclonal antibodies
(Mabs). Using escape mutants derived through this selection
process together with naturally occurring drift variants, the
antigenic epitopes have been mapped in the three-dimen-
sional structure of several HA subtypes (Caton et al., 1982;
Kaverin et al., 2002, 2004; Philpott et al., 1990; Tsuchiya et
al., 2001; Wiley et al., 1981).
The amino acid changes in the HA of escape mutants and
drift variants may have pleiotropic effects on the biologic
traits of the virus. It has been previously reported that the
amino acid substitutions can affect the affinity of HA for
sialic receptors (Daniels et al., 1987; Fleury et al., 1998;
Reading et al., 1997). Our previous data indicate that such
phenomena are frequent in escape mutants of H9 subtype
virus (Kaverin et al., 2004).004) 33–39
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antibodies on virus infectivity are not completely understood.
Several different neutralization mechanisms have been
described for IgM, IgA, and IgG antibodies (Knossow et
al., 2002; Outlaw andDimmock, 1990; Taylor andDimmock,
1985). In our previous studies on H5 (Kaverin et al., 2002)
and H9 (Kaverin et al., 2004) escape mutants, we encoun-
tered discrepancies between the ability of certain Mabs to
bind HA and their ability to neutralize infection and inhibit
hemagglutination. In addition to these discrepancies, we
frequently observed differences in the affinity of H9 escape
mutants for sialic receptors (Kaverin et al., 2004). These
observations prompted us to analyze the effect of the binding
of monoclonal antibodies to the mutant H9 HAs on their
ability to recognize different sialyl substrates. To reveal the
host-specific differences in the blocking of HA-receptor
interaction by the Mab, we used different types of sialic
receptors. The sialyl substrates contained either Neu5Aca2-
3Gal-, which is more typical for avian species (Katz et al.,
1987), or Neu5Aca2-6Gal-, which is more typical for human
and swine species (Katz et al., 1990), or amine-containing
sialyloligosaccharides, which are considered to be the most
similar to the natural receptors present on human cells (Eisen
et al., 1997).
In our earlier studies (Kaverin et al., 2004), a panel of 10
anti-H9 Mabs was used to obtain 18 escape mutants of a
mouse-adapted variant of the H9N2 influenza virus A/
Swine/Hong Kong/9/98 (Sw/HK/9/98-MA). The escape
mutants were selected with a two-step protocol, essentially
as described previously (Webster and Laver, 1980). The
passage of the wild-type mouse adapted strain in eggs did
not result in the selection of receptor-binding mutants. All of
the escape mutants and the wild-type virus were tested by
enzyme-linked immunosorbent assay (ELISA) and hemag-
glutination inhibition (HI) with the panel of anti-H9 Mabs,
and the hemagglutinin genes were sequenced. The results of
HI assay and ELISA coincided in most cases, except those
for MAbs 19A10 and 7B10, which reacted with the mutant
virus m19A10 in ELISA but not in HI assay, and those for
MAb 8C4, which behaved in this way with four mutants
that had a common amino acid change. These findings
prompted us to investigate the receptor-binding and the
antibody-binding properties of this set of H9 influenza virus
escape mutants.Table 1
Receptor-binding activity of H9 influenza virus escape mutants
Viruses Amino acid substitutions Kd (
6VSL
Sw/HK/9/98-MA – 0.19
m19A10 L226Q 1.02
m7B10 N193D 0.19
m3D11 N193D 0.18
m7B10-18G4 S116I, T135K, N193D 0.18
m7B10-18G4V T135K, N193D 0.19
a In each case, Kd = mean F SE  ta , n1, where ta—Student’s coefficient withResults
To investigate the fine mechanisms of competition
between antibody and receptor molecules we used a novel
approach based on the inhibition of binding of labeled
receptor analogs to viruses by monoclonal antibodies.
Affinity of H9 influenza virus escape mutants toward
biotinylated polyvalent synthetic sialoglycoconjugates
As a preliminary experiment, we estimated the affinity of
biotinylated sialoglycoconjugates to H9 escape mutants in
direct enzyme-linked assay. Namely, viruses were directly
coated onto 96-well plates and their receptor-binding
activities were measured using a set of Sug-PAA-biot
conjugates (3VSL-, 6VSL-, and 6VSLN-PAA-biot) (Matroso-
vich et al., 2000; Mochalova et al., 2003) followed by
streptavidin-peroxidase staining (Table 1).
In good agreement with our previous data obtained in a
competitive assay (Kaverin et al., 2004), the affinity of the
wild-type virus and all escape mutants except one with a
L226Q change was negligible for the 3VSL-bearing polymer,
which more closely resembles avian virus receptors (H3
numbering here and throughout text). This L226Q mutant
exhibited an increased affinity for 3VSL-PAA-biot (Table 1).
The amino acid substitution L226Q usually correlates with a
shift in the affinity of HA from the bhuman-typeQ sialic
receptors to the bavian-typeQ sialic receptors, that is, from
preference for a 2V–6Vlink to 2V–3Vlink between the sialic acid
residue and galactose. The four escape mutants carrying a
N193D mutation exhibited the decreased affinity for 6VSL-
PAA-biot (Table 1).
Competitive binding of monoclonal antibodies and sialic
substrates to H9 influenza virus escape mutants
To calculate the dissociation constants (Kd) of the
virus–antibody complexes we performed direct enzyme-
linked immunosorbent assays using the set of Mabs that
bind in ELISA but do not react in HI assay (Kaverin et al.,
2004). For each mutant virus, we used positive and
negative controls, that is, the Mabs that bound the escape
mutants and those that did not bind them, respectively
(Table 2). We used the Mab 15F1 as positive control forAM of Neu5Ac)a
N-PAA-biot 6VSL-PAA-biot 3VSL-PAA-biot
F 0.03 0.21 F 0.02 4.36 F 0.35
F 0.08 0.95 F 0.06 0.45 F 0.06
F 0.03 0.51 F 0.05 4.25 F 0.29
F 0.02 0.55 F 0.05 4.41 F 0.48
F 0.03 0.56 F 0.03 4.50 F 0.23
F 0.07 0.50 F 0.02 4.59 F 0.28
probability a (a = 0.90) was obtained in four independent experiments.
Table 2
Antibody-binding activity of H9 influenza virus escape mutants
Viruses Amino acid substitutions Kd  105 (AM of Mabs)a
19A10 (145)b 7B10 (145, 193) 3D11 (193, 226) 15F1 (162, 198) 8C4 (198, 189)
Sw/HK/9/98-MA – 1.98 F 0.18 1.87 F 0.21 0.90 F 0.34 1.18 F 0.13 2.24 F 0.46
m19A10 L226Q 3.61 F 0.54 4.67 F 0.39 N50 1.39 F 0.18 2.30 F 0.11
m7B10 N193D 1.94 F 0.18 N50 N50 1.14 F 0.22 5.02 F 0.31
m3D11 N193D 2.03 F 0.13 N50 N50 1.81 F 0.50 5.18 F 0.37
m7B10-18G4 S116I, T135K, N193D 1.85 F 0.21 N50 N50 1.12 F 0.14 5.07 F 0.51
m7B10-18G4V T135K, N193D 1.89 F 0.17 N50 N50 1.03 F 0.15 4.72 F 0.42
a In each case, Kd = mean F SE  ta , n1, where ta— Student’s coefficient with probability a (a = 0.90) was obtained in four independent experiments.
b Mutations in the H9 HA preventing HA–Mab interaction.
Fig. 1. Three-dimensional model of the H9 HA complexed with receptor
molecules (Ha et al., 2001). LSTc is shown in blue (pdb.1JSI), sialyl-
galactose of LSTa is shown in green (pdb.1JSH), the other residues of LSTa
were transferred from three-dimensional data of the H3 HA complexed with
LSTa (Eisen et al., 1997) (were kindly provided by Dr. Eisen) and are
shown in thin green lines. The amino acid substitutions are shown in pale
blue (DS Viewer Pro 5.0, Accelrys Inc. software). The overlapping
antigenic epitopes contain positions 145 and 193 ( the epitope of Mab
7B10), 193 and 226 (Mab 3D11), 198 and 189 (Mab 8C4), 162 and 198
(Mab 15F1), and 145 (Mab 19A10).
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m7B10-18G4V, and the Mab 8C4 for the m19A10 virus.
The Mab 3D11 was used as negative control for the
mutants m19A10 and m3D11, and the Mab 7B10 for the
others. All the viruses under study exhibited a high affinity
for all the Mabs except for the negative controls as
expected.
Our earlier studies (Kaverin et al., 2004) and the data of
the direct ELISA test have shown that only one amino acid
substitution D145E completely prevented the interaction
between H9 HA and the Mab 19A10, and therefore, this
position is within the area that forms the antigenic epitope of
this monoclonal antibody (Table 2). The mutations L226Q,
N193D, and N193T prevented the interaction between the
H9 escape mutants and the Mab 3D11, whereas the Mab
7B10 recognized an antigenic epitope including N193D,
N193T, and D145E amino acids. Therefore, the epitopes of
these two Mabs did not coincide, although two identical
escape mutants m7B10 and m3D11 with N193D change
were selected by the Mabs 7B10 and 3D11 (Kaverin et al.,
2004).
Fig. 1 shows that antigenic epitope of the Mab 7B10 is
in the right part of the receptor-binding site, whereas the
epitope of the Mab 3D11 overlaps with the upper and the
left parts of the receptor-binding site of the HA molecule,
that is, the place where the moieties of the receptor
adjacent to the sialic acid are located. The amino acids 198
and 189 are in the same place where the asialic parts of
3VSL-bearing polymer protrude. The mutations in these
positions prevent the interaction between HA H9 and the
Mab 8C4. The Mab 15F1 used as a positive control in this
study recognizes the epitope containing the amino acid
positions 162 and 198 (Kaverin et al., 2004) in the upper
part of the HA molecule over the receptor-binding site
(Fig. 1).
The competitive assay was based on the competition for
binding sites on the viral particle between nonlabeled Mab
and biotinylated polyvalent synthetic sialoglycoconjugates
or enzyme-labeled sialylglycoprotein fetuin compounds.
Serial dilutions of the Mabs were added to the labeled
receptor analogs and incubated with the viruses. The
concentration of Mabs that result in 50% inhibition of
receptor binding were calculated, and the values ofK50%Ing were compared with the Kd measured in direct
ELISA (Table 3). As a rule, these values were closely
related. If the Mab weakly bound to viruses (Kd N 50 
105 AM), it did not compete with the receptor. The Mabs
possessing high affinity for viruses efficiently displaced
the receptor molecule from the binding sites. Notably,
significant differences between the dissociation constants
measured in direct and competitive ELISAs were seen in
only three cases (Table 3). The Mabs 19A10 and 7B10
bound to the escape mutant m19A10 with high affinity
equal to the affinity for the parent virus, and successfully
competed with 6VSL- and 6VSLN-bearing polymers. How-
ever, it did not displace the 3VSL-bearing polymer and
fetuin. The Mab 8C4 interacted with the four escape
mutants containing the N193D mutation in the opposite
way, namely did not compete with 6VSLN trisaccharide and
Table 3
Receptor-binding activity of H9 influenza virus escape mutants in competitive reactions with monoclonal antibodies and biotinylated polyvalent synthetic
sialoglyconjugates
Viruses Competitive assay with K50%Ing  105 (AM of Mabs)a
19A10 (145)b 7B10 (145, 193) 3D11 (193, 226) 8C4 (198, 189) 15F1 (162, 198)
Sw/HK/9/98-MA fetuin 4.85 F 0.32 1.52 F 0.41 2.75 F 0.23 2.15 F 0.25 2.57 F 0.21
6VSL-PAA-biot 4.57 F 0.28 2.98 F 0.23 2.47 F 0.31 2.79 F 0.22 2.39 F 0.15
6VSLN-PAA-biot 4.32 F 0.22 2.44 F 0.37 2.38 F 0.20 2.34 F 0.19 2.48 F 0.32
3VSL-PAA-biot 4.69 F 0.37 2.68 F 0.28 2.51 F 0.37 2.53 F 0.28 2.13 F 0.25
m19A10 (L226Q) fetuin N100 N100 N100 2.17 F 0.24 1.87 F 0.26
6VSL-PAA-biot 5.87 F 0.43 4.22 F 0.29 N100 2.29 F 0.17 1.49 F 0.13
6VSLN-PAA-biot 6.08 F 0.46 4.69 F 0.38 N100 2.42 F 0.12 1.68 F 0.31
3VSL-PAA-biot N50 N50 N100 2.12 F 0.14 1.93 F 0.27
m7B10 (N193D) fetuin 4.76 F 0.30 N100 N100 1.88 F 0.26 1.62 F 0.35
6VSL-PAA-biot 4.64 F 0.25 N100 N100 2.02 F 0.20 1.38 F 0.24
6VSLN-PAA-biot 4.42 F 0.22 N100 N100 N50 1.43 F 0.28
3VSL-PAA-biot 4.58 F 0.36 N100 N100 2.28 F 0.35 1.67 F 0.21
m3D11 (N193D) fetuin 4.49 F 0.31 N100 N100 1.86 F 0.18 1.93 F 0.27
6VSL-PAA-biot 4.52 F 0.25 N100 N100 2.06 F 0.33 1.77 F 0.31
6VSLN-PAA-biot 4.82 F 0.36 N100 N100 N50 1.56 F 0.44
3VSL-PAA-biot 4.61 F 0.33 N100 N100 2.38 F 0.37 1.84 F 0.19
m7B10-18G4
(S116I, T135K, N193D)
fetuin 4.75 F 0.22 N100 N100 2.21 F 0.16 1.27 F 0.15
6VSL-PAA-biot 4.67 F 0.18 N100 N100 2.35 F 0.35 1.84 F 0.28
6VSLN-PAA-biot 4.40 F 0.32 N100 N100 N50 1.44 F 0.31
3VSL-PAA-biot 4.53 F 0.29 N100 N100 2.55 F 0.22 1.56 F 0.24
m7B10-18G4V
(T135K, N193D)
fetuin 4.37 F 0.25 N100 N100 1.90 F 0.14 1.06 F 0.07
6VSL-PAA-biot 4.55 F 0.28 N100 N100 2.26 F 0.31 1.43 F 0.19
6VSLN-PAA-biot 4.48 F 0.22 N100 N100 N50 1.19 F 0.25
3VSL-PAA-biot 4.68 F 0.35 N100 N100 1.89 F 0.27 1.77 F 0.28
a In each case, K50%IngF SE  ta , n1, where ta—Student’s coefficient with probability a (a = 0.90) was obtained in four independent experiments.
b Mutations in the H9 HA preventing HA–Mab interaction.
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recognizes the epitope overlapping with the receptor-
binding site, and the Mab 15F1, that interacts with the
area located directly over the receptor-binding site,
displaced all the types of receptors.Discussion
Data on the receptor-binding specificity of influenza
viruses are important for understanding the mechanisms of
virus evolution and interspecies transfer. To mimic the
natural process of polyvalent cooperative interactions
between the influenza virus and its receptor on the surface
of the host cell, we studied the binding of H9 escape
mutants to sialyloligosaccharides in the presence and
absence of monoclonal antibodies.
Among the amino acid substitutions in H9 HA, the
change L226Q in the receptor-binding site is of special
interest. This replacement plays a prominent role in the
receptor binding specificity. It has been shown that residue
226 of HA is the key amino acid in the recognition of
Neu5Aca2-3Gal by H2, H3, and H9 influenza viruses
(Connor et al., 1994; Matrosovich et al., 2000, 2001). The
selection of escape mutants with substitutions in position
226 and a subsequent change in receptor affinity has been
described for H3 subtype viruses (Daniels et al., 1987).Competitive ELISAs demonstrated that this L226Q
replacement, which leads to a dramatic increase in affinity
for 3VSL, allows the virus–Mab complexes to react with
3VSL-PAA-biot, but not with 6VSL- or 6VSLN-PAA-biot (Table
3). This disparity could not be explained by different
affinity of virus to 3VSL- and 6VSL-bearing polymers, since
the affinity values were nearly equal (Table 1). So, the only
explanation was the different orientation of distal parts of
3VSL- and 6VSL receptors’ molecules that resulted in the
competition of 19A10 and 7B10 antibody for 6VSL receptors
and the absence of competition for 3VSL-groups. This is in
agreement with the data of X-ray analysis of the complexes
of H9 hemagglutinin with receptor molecules (Ha et al.,
2001). The third saccharide and more proximal moieties of
3Vsialo-sugar receptors contact the amino acids 187, 189,
and 198 situated in the upper left corner of receptor-binding
site. For this reason, the antibody attached to 145 amino
acid in the lower right part of the receptor-binding site fails
to compete with receptor molecule. On the contrary, the
stalk of 6VSLN receptors contacts the epitopes of the Mabs
19A10 and 7B10 and competes with these antibodies.
It is not surprising that the m19A10 mutant–antibody
complexes also bind to fetuin because the latter has both
Neu5Aca2-3Gal- and Neu5Aca2-6Gal-containing recep-
tors. The hemagglutinin is the component of influenza virus
membrane against which infectivity-neutralizing antibodies
are directed, and the previous results indicated that
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inhibition of receptor binding (Bizebard et al., 1995).
Moreover, the inhibition of receptor binding is an obligatory
component of neutralization (Fleury et al., 1999). The amino
acid change L226Q in the H9 HA receptor-binding site may
provide an advantage in overcoming the neutralizing effects
of antibodies by allowing the recognition of host cell
receptors despite the presence of antibody.
Mutants containing the N193D replacement have a
reduced affinity to 6VSL-PAA-biot but not to 6VSLN-PAA-
biot. Thus, they are able to distinguish 6VSL from 6VSLN
(Table 1). The preferential binding of early H1N1 human
influenza viruses to 6VSLN-receptor has been shown
(Gambaryan et al., 1997, 1999; Matrosovich et al., 1997),
and such receptor-binding specificity is also typical for
contemporary H3N2 human viruses (Mochalova et al.,
2003).
The 6V-SLN has been proposed by Eisen et al. (1997) to
be more similar to the human receptor than is 6VSL. The
folded conformation of 6VSLN, which is stabilized by a
hydrogen bond and van der Waals contacts between
Neu5Ac and GlcNAc moieties, suits the architecture of
the hemagglutinin receptor-binding site much better than the
extended conformation of 6VSL trisaccharide. In the H9 HA
complex with pentasaccharide LSTc, terminated 6VSLN-
group, the three proximal saccharides (GlcNAc-3, Gal-4,
Glc-5) fold back over the top of the sialic acid and exit from
the site at the front-right and contact the binding site at the
loop formed by residues 125–137, at the 150 loop, and at
Asn-193 (Ha et al., 2001).
The results of competitive ELISAs between Mab 8C4
and biotinylated sialyloligosaccharides suggest that the
increased affinity toward 6VSLN-PAA-biot caused by the
N193D mutation confers an ability to bind 6VSLN in the
presence of the bound 8C4 antibody (Table 3). As the
epitope of this antibody is in region of 189 and 198 amino
acids, it is not surprising that it competes with 3VSL receptor
molecules, but not with 6VSLN.
The presented data demonstrate that residues 226 and
193 of the H9 HA are involved not only in the specificity of
host-cell recognition but also in the ability of viruses
carrying these mutations to escape the neutralizing effects
of antibodies that neutralize infectivity by preventing virus
from binding to cells (Knossow et al., 2002). The HA
changes that allow H9 viruses to escape the neutralizing
effects of bound antibody can therefore also result in the
switching of receptor specificities and represent an alter-
native to previously described mechanisms of escape from
neutralization by antibodies (Fleury et al., 1998). The co-
selection of antigenic and biologic variants has implications
for the evolution of influenza viruses in the face of
immunological pressures. These data suggest that in natural
conditions immune selection can produce variants having
both altered host specificity and an ability to escape a host’s
immune defense mechanism, factors important in consider-
ing the natural evolution of H9 influenza viruses, a plausiblecandidate for the next pandemic agent (Webby and Webster,
2001).Materials and methods
Materials
For receptor-binding assays, 96-well PV-microtiter plates
from Costar, USA, and horseradish peroxidase-streptavidin
conjugate and o-phenylenediamnine from Boehringer Man-
nheim, Germany were used. The synthesis of biotinylated
polyvalent synthetic sialoglycoconjugates was described
earlier (Bovin et al., 1993; Mochalova et al., 2003; Tuzikov
et al., 2000). According to monosaccharide analysis data,
the molar content of Sug in all conjugates is 20%, and the
molar content of biotin in Sug-PAA-biot is 5%.
Viruses
The influenza virus A/Swine/Hong Kong/9/98 (H9N2)
(GenBank accession no. AF222810), from the virus
repository of the Department of Infectious Diseases at St.
Jude Children’s Research Hospital, was adapted to mice by
serial lung-to-lung passage (Kaverin et al., 2004). Escape
mutants of the mouse-adapted variant, which was desig-
nated Sw/HK/9/98-MA, were selected with a panel of anti-
H9 Mabs (Kaverin et al., 2004). The viruses were
propagated in 9- to 10-day-old embryonated chicken eggs.
For studies on virus binding, the virus-containing allantoic
fluids were clarified from cellular debris by low-speed
centrifugation and used without further purification. Nucleo-
tide sequences used in this study are available in the
GenBank database under the accession numbers AY428485,
AY428494, AY428495, AY428497, AY428499, AY428500
(Kaverin et al., 2004).
Monoclonal antibodies
A panel of virus-neutralizing monoclonal antibodies to
the HA of H9 strains was used. This panel included six
MAbs to A/Duck/Hong Kong/Y280/97 (H9N2). The MAbs
were produced by the Department of Infectious Diseases, St.
Jude Children’s Research Hospital, by the method of Kohler
and Milstein (1976).
Solid-phase direct binding assay for measuring
receptor-binding activity
The binding specificity of H9 influenza virus escape
mutants was investigated in a direct binding assay. Plates
were coated with viruses at a titer of 4–8 hemagglutina-
tion units (50 Al/well) at 4 8C for 16 h followed by
washing with 0.05% Tween 20 in phosphate-buffered
saline (PBS-T). After the addition of Sug-PAA-biot, 30 Al/
well in PBS supplemented with 0.02% of Tween 20;
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neuraminidase inhibitor (2,3-didehydro-2,4-dideoxy-4-
amino-N-acetyl-d-neuraminic acid) (working buffer) plates
were incubated at 4 8C for 1 h. The starting concentration
of Sug-PAA-biot was 20 AM on sialic acid; 2-fold serial
dilutions were used. Plates were washed with a cold PBS-
T and incubated with streptavidin–peroxidase in the
working buffer at 4 8C for 1 h. After washing, 100 Al/
well of substrate solution (0.1 M sodium acetate, pH 5.0,
containing 4 mM o-phenylendiamine and 0.004% H2O2)
was added and the reaction was stopped with 2 M H2SO4.
Optical density was determined at 492 nm with a
Multiscan plate reader (Labsystems, Finland). The disso-
ciation constants (Kd) were determined as Neu5Ac
concentration at the point Amax/2 of Scatchard plots.
The reported data represent the mean of at least four
individual experiments for each mutant virus.
The binding of H9 escape mutants to fetuin was also
performed in a direct solid-phase assay with the immobi-
lized virus and horseradish peroxidase-conjugated fetuin
(Gambaryan and Matrosovich, 1992).
Serologic methods
Direct enzyme-linked immunosorbent assay (ELISA)
was performed essentially as described by Philpott et al.
(1989) with some modifications. Briefly, 4-8 hemaggluti-
nating units of virus were bound to each well at 4 8C in
PBS pH 7.4. Twofold serial dilutions of MAbs in PBS
containing 0.05% Tween 20 and 5% bovine serum were
added, and plates were incubated for 1 h at room
temperature, washed five times with PBS-T, and incubated
for 1 h with horseradish peroxidase-conjugated anti-mouse
goat immunoglobulin (Sigma). The enzymatic activity was
detected by hydrolysis with 0.004% hydrogen peroxide in
the presence of 4 mM o-phenylenediamine in 0.1 M
citrate-phosphate buffer, pH 5.0 and was quantified by
measuring the absorbance at a wavelength of 492 nm. The
Kd was determined as the concentration of Mab at the
point Amax/2 of Scatchard plots. The reported data
represent the mean of dissociation constants of virus–
Mab complexes calculated in three or four individual
experiments for each escape mutant.
The competitive assay was based on the competition for
binding sites on the viral particle between nonlabeled
monoclonal antibody and enzyme-labeled sialylglycoprotein
fetuin (Matrosovich et al., 1993) or biotinylated polyvalent
synthetic sialoglycoconjugates. Briefly, influenza viruses
diluted to the titer of 4–8 hemagglutination units were
adsorbed onto the wells of 96-well PV-microtiter plates from
Costar, USA (50 Al/well) at 4 8C for 16 h. After unbound virus
was washed off with PBS-T, 50 Al of solutions containing a
fixed amount of fetuin labeled with horseradish peroxidase or
biotinylated polyvalent synthetic sialoglycoconjugates and a
variable amount of nonlabeled monoclonal antibody were
added to the plate, which was then incubated for 1 h at 4 8C.The solutions were prepared in PBS supplemented with
0.02% bovine serum albumin, 0.02% Tween 20, and 3 AM of
the neuraminidase inhibitor (2,3-didehydro-2,4-dideoxy-4-
amino-N-acetyl-d-neuraminic acid). After this incubation,
the plates were washed with PBS-T, and the amount of
labeled fetuin or biotinylated polyvalent synthetic sialogly-
coconjugates was determined by using the standard o-
phenylenediamine chromogenic substrate.
The dissociation constants of the virus complexes with
Mabs were calculated for each concentrations of the
compound used in the competitive reaction, and the results
were averaged.Acknowledgments
These studies were supported by NATO Collaborative
Linkage Grant 979155 and by grants 02-04-48109, 03-04-
48353, and 04-04-48819 from the Russian Foundation for
Basic Research (RFBR). We thank Richard J. Webby for
critical comments and for editorial assistance.References
Bizebard, T., Gigant, B., Rigolet, P., Rasmussen, B., Diat, O., Bosecke, P.,
Wharton, S.A., Skehel, J.J., Knossow, M., 1995. Structure of influenza
virus haemagglutinin complexed with a neutralizing antibody. Nature
376 (6535), 92–94.
Bovin, N.V., Korchagina, E.Yu., Zemlyanukhina, T.V., Byramova, N.E.,
Galanina, O.E., Zemlyakov, A.E., Ivanov, A.E., Zubov, A.E., Mocha-
lova, L.V., 1993. Synthesis of polymeric neoglycoconjugates based on
N-substituted polyacrylamides. Glycoconjugate J. 10, 142–151.
Caton, A.J., Brownlee, G.G., Yewdell, J.M., Gerhard, W., 1982. The
antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H3
subtype). Cell 31, 417–427.
Connor, R.J., Kawaoka, Y., Webster, R.G., Paulson, J.C., 1994. Receptor
specificity in human, avian, and equine H2 and H3 influenza virus
isolates. Virology 205, 17–23.
Cox, N.J., Bender, C., 1995. The molecular epidemiology of influenza
viruses. Virology 6, 359–370.
Daniels, R.S., Jeffries, S., Yates, P., Schild, G.C., Rodgers, G.N., Paulson,
J.C., Wharton, S.A., Douglas, A.R., Skehel, J.J., Wiley, D.C., 1987. The
receptor binding and membrane fusion properties of influenza virus
variants selected using anti-haemagglutinin monoclonal antibodies.
EMBO J. 6, 1459–1465.
Eisen, M.B., Sabesan, S., Skehel, J.J., Wiley, D.C., 1997. Binding of the
influenza A virus to cell-surface receptors: structures of five
hemagglutinin–sialyloligosaccharide complexes determined by X-ray
crystallography. Virology 232, 19–31.
Fleury, D., Wharton, S.A., Skehel, J.J., Knossow, M., Bizebard, T., 1998.
Antigen distortion allows influenza virus to escape neutralization. Nat.
Struct. Biol. 5 (2), 119–123.
Fleury, D., Barre`re, B., Bizebard, T., Daniels, R., Skehel, J.J., Knossow, M.,
1999. A complex of influenza hemagglutinin with a neutralizing
antibody that binds outside the virus receptor binding site. Nat. Struct.
Biol. 6, 530–534.
Gambaryan, A.S., Matrosovich, M.N., 1992. A solid-phase enzyme-linked
assay for influenza virus receptor-binding activity. J. Virol. Methods 39,
111–123.
N. Ilyushina et al. / Virology 329 (2004) 33–39 39Gambaryan, A.S., Tuzikov, A.B., Piskarev, V.E., Yamnikova, S.S., Lvov,
D.K., Robertson, J.S., Bovin, N.V., Matrosovich, M.N., 1997.
Specification of receptor-binding phenotypes of influenza virus isolates
from different hosts using synthetic sialylglycopolymers: non-egg-
adapted human H1 and H3 influenza A and influenza B viruses share a
common high binding affinity for 6(-sialyl(N-acetyllactosamine).
Virology 232, 345–350.
Gambaryan, A.S., Robertson, J.S., Matrosovich, M.N., 1999. Effects of
egg-adaptation on the receptor-binding properties of human influenza A
and B viruses. Virology 258, 232–239.
Ha, Y., Stevens, D.I., Skehel, J.J., Wiley, D.C., 2001. X-ray structures of H5
Avian and H9 swine hemagglutinins bound to avian and human receptor
analogs. Proc. Natl. Acad. Sci. U.S.A. 98, 11181–11186.
Jackson, D.C., Nestorowicz, A., 1985. Antigenic determinants of influenza
virus hemagglutinin. Virology 145, 72–83.
Katz, J.M., Naeve, C.M., Webster, R.G., 1987. Host cell-mediated variation
in H3N2 influenza viruses. Virology 156, 386–395.
Katz, J.M., Wang, M., Webster, R.G., 1990. Direct sequencing of the HA
gene of influenza (H3N2) virus in original clinical samples reveals
sequence identity with mammalian cell-grown virus. J. Virol. 64,
1808–1811.
Kaverin, N.V., Rudneva, I.A., Ilyushina, N.A., Varich, N.L., Lipatov, A.S.,
Smirnov, Y.A., Govorkova, E.A., Gitelman, A.K., Lvov, D.K., Webster,
R.G., 2002. Structure of antigenic sites on the haemagglutinin molecule
of H5 influenza virus and phenotypic variation of escape mutants.
J. Gen. Virol. 83, 2497–2505.
Kaverin, N.V., Rudneva, I.A., Ilyushina, N.A., Lipatov, A.S., Krauss, S.,
Webster, R.G., 2004. Structural differences among hemagglutinins of
influenza A virus subtypes are reflected in their antigenic architecture:
analysis of H9 escape mutants. J. Virol. 78, 290–299.
Knossow, M., Gaudier, M., Douglas, A., Barre`re, B., Bizebard, T., Barbey,
C., Gigant, B., Skehel, J.J., 2002. Mechanism of neutralization of
influenza virus infectivity by antibodies. Virology 302/2, 294–298.
Kohler, G.,Milstein, C., 1976.Derivation of specific antibody-producing tissue
culture and tumor lines by cell fusion. Eur. J. Immunol. 6, 511–519.
Matrosovich, M.N., Gambaryan, A.S., Tuzikov, A.B., Byramova, N.A.,
Mochalova, L.V., Golbraikh, A.A., Shenderovich, M.D., Finne, J.,
Bovin, N.V., 1993. Probing of the receptor-binding sites of the H1 and
H3 influenza virus hemagglutinins by synthetic and natural sialosides.
Virology 196, 111–123.
Matrosovich, M.N., Gambaryan, A.S., Teneberg, S., Piskarev, V.E.,
Yamnikova, S.S., Lvov, D.K., Robertson, J.S., Karlsson, K.A., 1997.
Avian influenza A viruses differ from human viruses by recognition of
sialyloligosaccharides and gangliosides and by a higher conservation of
the HA receptor-binding site. Virology 233, 224–234.
Matrosovich, M., Tuzikov, A., Bovin, N., Gambaryan, A., Klimov, A.,
Castrucci, M.R., Donatelli, I., Kawaoka, Y., 2000. Early alterations ofthe receptor-binding properties of H1, H2, and H3 avian influenza virus
hemagglutinins after their introduction into mammals. J. Virol. 74,
8502–8512.
Matrosovich, M.N., Krauss, S., Webster, R.G., 2001. H9N2 influenza A
viruses from poultry in Asia have human virus-like receptor specificity.
Virology 281, 156–162.
Mochalova, L., Gambaryan, A., Romanova, J., Tuzikov, A., Chinarev, A.,
Katinger, D., Katinger, H., Egorov, A., Bovin, N., 2003. Receptor-
binding properties of modern human influenza viruses primarily
isolated in Vero and MDCK cells and chicken embryonated eggs.
Virology 313, 473–480.
Outlaw, M.C., Dimmock, N.J., 1990. Mechanisms of neutralization of
influenza virus on mouse tracheal epithelial cells by mouse monoclonal
polymeric IgA and polyclonal IgM directed against the viral haemag-
glutinin. J. Gen. Virol. 1, 69–76.
Philpott, M., Easterday, B.C., Hinshaw, V.S., 1989. Neutralizing epitopes of
the H5 hemagglutinin from a virulent avian influenza virus and their
relationship to pathogenicity. J. Virol. 63, 3453–3458.
Philpott, M., Hioe, C., Sheerar, M., Hinshaw, V., 1990. Hemagglutinin
mutations related to attenuation altered cell tropism of a virulent avian
influenza A virus. J. Virol. 64, 2941–2947.
Raymond, R.L., Caton, A.J., Cox, N.J., Kendal, A.P., Brownlee, G.C.,
1986. The antigenicity and evolution of influenza H1 hemagglutinin,
from 1950–1957 and 1977–1983: two pathways from one gene.
Virology 148, 275–287.
Reading, P.C., Morey, L.S., Crouch, I.C., Anders, M.E., 1997. Collectin-
mediated antiviral host defense of the lung: evidence from influenza
virus infection of mice. J. Virol. 71, 8204–8212.
Taylor, H.P., Dimmock, N.J., 1985. Mechanisms of neutralization of
influenza virus by IgM. J. Gen. Virol. 4, 903–907.
Tsuchiya, E., Sugawara, K., Hongo, S., Matsuzaki, Y., Muraki, Y., Li, Z.-N.,
Nakamura, K., 2001. Antigenic structure of the haemagglutinin of human
influenza A/H2N2 virus. J. Gen. Virol. 82, 2475–2484.
Tuzikov, A.B., Gambaryan, A.S., Juneja, L.R., Bovin, N.V., 2000.
Conversion of complex sialyloligosaccharides into polymeric conju-
gates and their anti-influenza virus inhibitory potency. J. Carbohydr.
Chem. 19, 1191–1200.
Webby, R.G., Webster, R.G., 2001. Emergence of influenza A viruses. Phil.
Trans. R. Soc. London, B 356, 1818–1828.
Webster, R.G., Laver, W.G., 1980. Determination of the number of
nonoverlapping antigenic areas on Hong Kong (H3N2) influenza virus
hemagglutinin with monoclonal antibodies and the selection of
variants with potential epidemiological significance. Virology 104,
139–148.
Wiley, D.C., Wilson, I.A., Skehel, J.J., 1981. Structural identification of the
antibody-binding sites of Hong Kong influenza hemagglutinin and their
involvement in antigenic variation. Nature 289, 373–378.
